Attovia Therapeutics, a clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases, priced its upsized initial public offering at $17.00 per share. The San Carlos-based company will sell 17,000,000 shares, generating gross proceeds of $289.0 million before underwriting costs and expenses. Attovia has also granted underwriters a 30-day option to purchase up to 2,550,000 additional shares at the offering price. The company's common stock is expected to begin trading on the Nasdaq Global Market on 5 August 2026 under the ticker symbol "ATTO", with the offering closing on 6 August 2026. Morgan Stanley, Leerink Partners, Citigroup, and RBC Capital Markets are serving as joint book-running managers, whilst LifeSci Capital acts as passive book-running manager.

Attovia Therapeutics has disclosed that Venbio Global Strategic Fund IV and Goldman Sachs-affiliated entities each hold 5% or greater stakes in the company. This follows Attovia's oversubscribed $105 million Series B financing round, led by Goldman Sachs Alternatives with participation from venBio and other investors. Since launching in June 2023, Attovia has raised $165 million in total. The Series B proceeds will advance lead programmes ATTO-1310 and ATTO-002 through initial clinical readouts and further develop its ATTOBODY platform. Goldman Sachs Alternatives appointed Colin Walsh to Attovia's board of directors. VenBio has been a consistent investor since Attovia's inception. The increased ownership reflects investor confidence in Attovia's pipeline and proprietary platform for developing bi-specific therapeutics targeting immune-mediated diseases.

Attovia Therapeutics, a San Carlos, CA-based privately-held, clinical-stage biopharma company, raised $90M in Series C funding